Predicted to enable calcium ion binding activity. Predicted to be located in membrane. Orthologous to human EFCAB14 (EF-hand calcium binding domain 14); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-sulfonyldiphenol; acrylamide.
EF-hand calcium-binding domain-containing protein 14; hypothetical protein LOC298425; LOC298425; RGD1310351; similar to RIKEN cDNA 4732418C07; uncharacterized protein LOC298425
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of EFCAB14 protein]
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of EFCAB14 protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of EFCAB14 protein
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of EFCAB14 protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of EFCAB14 protein
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFCAB14 mRNA
[perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of EFCAB14 mRNA and [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of EFCAB14 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFCAB14 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFCAB14 mRNA